Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A new cardioprotective drug for acute treatment of myocardial infarction

Project description

Innovative treatment of myocardial infarction

Ischemic Heart Disease causes over 1.7 million deaths annually in the EU, primarily due to heart attacks (Myocardial Infarction - MI). Following a heart attack, heart failure (HF) affects over 26 million people globally. While current treatments save lives, they can also cause additional heart damage through inflammatory reactions. The EIC-funded CardioProtectMI project will evaluate the clinical effectiveness of RTP-026 through a Phase IIa proof-of-principle study and a Phase IIb proof-of-concept study. RTP-026 aims to modulate the immune system and reduce inflammation triggered by MI, thereby minimising heart damage and lowering the risk of HF and death. Preclinical data suggests that RTP-026 could reduce post-heart attack HF by over 20 %.

Objective

Ischemic Heart Disease kills more than 1.7M people/year in the EU, the vast majority via a heart attack (Myocardial Infarction - MI). Heart failure (HF) is the major cause of death after MI with a prevalence of >26M individuals globally. While current treatment involving restoration of blood flow to the heart saves the MI patients life it also causes additional damage to the heart through an inflammatory reaction (reperfusion injury).
ResoThers leading drug candidate, RTP-026, is an immunomodulating therapeutic aimed at resolving inflammation triggered during MI, thereby reducing damage to the heart and significantly decreasing risk of HF and death. Pre-clinical data suggests RTP-026 could reduce post-MI HF by >20%. A Phase I study has been conducted to determine safety and tolerability of RTP-026 in Healthy Volunteers. With the EIC we aim to validate RTP-026 clinical effectiveness by means of a Phase IIa patient proof of principle study and Phase IIb proof of concept study.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

RESOTHER PHARMA A/S
Net EU contribution
€ 2 499 999,00
Address
DRONNINGGAARDS ALLE 136
2840 Holte
Denmark
SME
Yes
Region
Danmark Hovedstaden Nordsjælland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 770 625,00